Igarashi A, Nakagawa H, Morita A, Okubo Y, et al. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1). J Dermatol 2021 Feb 25. doi: 10.1111/1346-8138.15789.
PMID: 33630387